This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Malaria	β -Ketoacyl-acyl carrier protein synthase III (PfKASIII)	An SAR study characterized a series of sulfides, sulfonamides and sulfonyls as PfKASIII inhibitors that could be useful for treating malaria. <i>In vitro</i> , 8 of the 13 PfKASIII inhibitors inhibited growth of <i>Plasmodium falciparum</i> parasites at concentrations <10 μ M. Next steps include studies in animal models of malaria to determine <i>in vivo</i> efficacy and toxicity of the compounds. SciBX 2(6) ; doi:10.1038/scibx.2009.230 Published online Feb. 12, 2009	Unpatented; unlicensed	Lee, P. <i>et al. J. Med. Chem.</i> ; published online Feb. 3, 2009; doi:10.1021/jm8008103 Contact: Norman C. Waters, Australian Army Malaria Institute, Enoggera, Queensland, Australia e-mail: norman.waters@us.army.mil